| Name | Title | Contact Details |
|---|
Selvita is a preclinical Contract Research Organization providing multidisciplinary support in resolving the unique challenges of research within area of drug discovery, regulatory studies, as well as research and development. Selvita is also a major shareholder in Ardigen – a bioinformatics company harnessing advanced Artificial Intelligence methods for novel precision medicine. In January 2021, Selvita acquired 100% of shares in Fidelta d.o.o., substantially expanding its scope of drug discovery services in infectious diseases, inflammation, and fibrosis and building a competitive advantage in areas such as DMPK, in vivo pharmacology, and toxicology. Selvita was established in 2007 and currently employs almost 800 professionals, of which over 40% hold a Ph.D. title. Selvita is headquartered in Krakow, Poland, with a second research site in Poznan, Poland, while Fidelta is located in Zagreb, Croatia. Selvita`s international offices are located in Cambridge, MA, and San Francisco Bay Area, in the U.S., as well as in Cambridge, UK.
Southwest FLA Regional Imaging is a Punta Gorda, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ALERT Life Sciences Computing is a Reston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins.
Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion`s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF) to activate the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. Enrollment is ongoing in a placebo-controlled Phase 3 registration trial examining the efficacy of ANG-3777 in reducing the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients at risk for kidney dysfunction. ANG-3777 is also in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach.